戻る Agenda
[S11] How Will the Development and NDA Activities in Japan Change in View of the Future of AI Translation?
Session Chair(s)
Michio Tanaka
Executive Officer, Division Vice president, Science & Data Technology Division
AstraZeneca K.K., Japan
Following 2018 Japan annual meeting, the current status of AI translation in the pharmaceutical field will be reviewed. We will discuss how industrygovernment- academia collaboration should be promoted to further improve quality of AI translation, based on the status and issues of quality improvement before and after adaptation in pharmaceutical companies and success cases in other industries.
Speaker(s)
R&D Head Club's WGs report: Quality-improvement before and after Adaptation
Kiyoshi Kinoshita, PhD
MSD K.K., Japan
Manager, Regulatory Affairs, Area Japan Development
Key for Success of Machine Translation - How to Perform Post-Edit Effectively
Toshiyuki Shigematsu
Novartis Pharma Co Ltd, Japan
Medical Writer
A Case of Company-wide Introduction of AI Translation Technology -Background, Process and Future Prospects
Yusuke Asoh
Daiichi Sankyo Co., Ltd, Japan
Manager, IT Strategy Department